Articles

Videos

Podcasts

Clinical

The ability of an anti-interleukin-23 antibody to bind to key immune system components may help neutralize a key driver of inflammation right at its cellular source.

New Binding Mechanism Science Driving Therapeutic Insight in Immune-Mediated Diseases

Ustekinumab is the first and only biologic that targets both cytokines interleukin (IL)-12 and IL-23.

Ustekinumab Approved to Treat Pediatric Patients With Active Psoriatic Arthritis

Tapinarof (Vtama) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

Daily Medication Pearl: Tapinarof (Vtama) 

People living with psoriatic arthritis deserve to be informed about ways to approach disease management holistically and with a personalized approach.

Holistic Psoriatic Arthritis Care: Why Well-Being Should Be Incorporated Into the Treatment Paradigm

The study results support a hypothesis for a differentiated mechanism from risankizumab, the company says.

New Data Show J&J Unit’s Tremfya Binds to Both Inflammatory Cells, Interleukin (IL)-23

Agency greenlights secukinumab’s use for pediatric Treatment of enthesitis-related arthritis and Juvenile psoriatic arthritis.

FDA Approves Cosentyx for New Indications

Abatacept is also approved for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and moderate to severe polyarticular juvenile idiopathic arthritis for children 2 years of age and older.

FDA Approves Abatacept With Calcineurin Inhibitor for Prophylaxis of Acute Graft Versus Host Disease

The safety profile observed in patients with active psoriatic arthritis administered upadacitinib was consistent with the safety profile observed in patients with rheumatoid arthritis.

Upadacitinib Receives FDA Approval for Treatment of Active Psoriatic Arthritis

Apremilast is indicated for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behçet disease.

Daily Medication Pearl: Apremilast (Otezla)

The investigators concluded that a definite statement on risk or management recommendations cannot be made based on currently published data.